(Reuters) - Japan's Takeda Pharmaceutical Co Ltd said U.S. regulators had extended their review of its diabetes drug alogliptin, requesting additional data on what the company hopes will be the successor to its top-selling Actos drug.
Source: http://feeds.reuters.com/~r/reuters/healthNews/~3/aj9c0mtVrgY/us-takedapharmaceutical-idUSBRE83P06020120426
make money best news online money internet business Current news latest news
No comments:
Post a Comment